Menu
Back to Journals » ImmunoTargets and Therapy
ImmunoTargets and Therapy
ISSN: 2253-1556
- View all (147)
- Volume 12, 2023 (6)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Journal Articles:
- 147 records -
Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives
Ferrara CA, La Rocca G, Ielo G, Libra A, Sambataro G
ImmunoTargets and Therapy 2023, 12:79-89
Published Date: 26 July 2023
Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]
Wiggins S, Levit NA
ImmunoTargets and Therapy 2023, 12:77-78
Published Date: 25 May 2023
Association of Toll-like Receptors 1, 2, 4, 6, 8, 9 and 10 Genes Polymorphisms and Susceptibility to Pulmonary Tuberculosis in Sudanese Patients
Mhmoud NA
ImmunoTargets and Therapy 2023, 12:47-75
Published Date: 6 April 2023
Novel Immunotherapies for Myasthenia Gravis
Nair SS, Jacob S
ImmunoTargets and Therapy 2023, 12:25-45
Published Date: 4 April 2023
A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
Zhu J, Li G, Zhang Z, Wang Y
ImmunoTargets and Therapy 2023, 12:17-23
Published Date: 19 February 2023
Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L, Luo M, Wu S, Yang C, Huang L, Fu L
ImmunoTargets and Therapy 2023, 12:1-16
Published Date: 4 January 2023
β-Glucan “Trained Immunity” Immunomodulatory Properties Potentiate Tissue Wound Management and Accelerate Fitness Recover
Renke G, Baesso T, Paes R, Renke A
ImmunoTargets and Therapy 2022, 11:67-73
Published Date: 17 October 2022
A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects
Celik M, Fuehrlein B
ImmunoTargets and Therapy 2022, 11:55-66
Published Date: 29 September 2022
The Meat of the Matter: Understanding and Managing Alpha-Gal Syndrome
Macdougall JD, Thomas KO, Iweala OI
ImmunoTargets and Therapy 2022, 11:37-54
Published Date: 15 September 2022
Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2
Wang LG, Wang L
ImmunoTargets and Therapy 2022, 11:23-35
Published Date: 18 May 2022
Immunotargets and Therapy for Prurigo Nodularis
Labib A, Ju T, Vander Does A, Yosipovitch G
ImmunoTargets and Therapy 2022, 11:11-21
Published Date: 26 April 2022
Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
Lin AY, Schnitter JM, Gordon LI
ImmunoTargets and Therapy 2022, 11:1-10
Published Date: 23 February 2022
Pathophysiology of Non-IgE-Mediated Food Allergy
Zhang S, Sicherer S, Berin MC, Agyemang A
ImmunoTargets and Therapy 2021, 10:431-446
Published Date: 29 December 2021
Understanding and Managing Severe Asthma in the Context of COVID-19
Kong-Cardoso B, Ribeiro A, Aguiar R, Pité H, Morais-Almeida M
ImmunoTargets and Therapy 2021, 10:419-430
Published Date: 11 December 2021
The Role of IL-17 Cytokines in Psoriasis
Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T
ImmunoTargets and Therapy 2021, 10:409-418
Published Date: 24 November 2021
Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies
Karmakar S, Pal P, Lal G
ImmunoTargets and Therapy 2021, 10:387-407
Published Date: 1 November 2021
The Role of Complement in Synaptic Pruning and Neurodegeneration
Gomez-Arboledas A, Acharya MM, Tenner AJ
ImmunoTargets and Therapy 2021, 10:373-386
Published Date: 24 September 2021
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson HN
ImmunoTargets and Therapy 2021, 10:343-371
Published Date: 9 September 2021
Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
Arneson LC, Carroll KJ, Ruderman EM
ImmunoTargets and Therapy 2021, 10:333-342
Published Date: 28 August 2021
B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20
Levy M, Mealy MA
ImmunoTargets and Therapy 2021, 10:325-331
Published Date: 20 August 2021
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda R, Dimou P, D'Souza RR, Klampatsa A
ImmunoTargets and Therapy 2021, 10:313-323
Published Date: 5 August 2021
Alopecia Areata: An Autoimmune Disease of Multiple Players
Suchonwanit P, Kositkuljorn C, Pomsoong C
ImmunoTargets and Therapy 2021, 10:299-312
Published Date: 29 July 2021
Contribution of Toll-Like Receptors and the NLRP3 Inflammasome in Rheumatoid Arthritis Pathophysiology
Unterberger S, Davies KA, Rambhatla SB, Sacre S
ImmunoTargets and Therapy 2021, 10:285-298
Published Date: 28 July 2021
Complement Inhibition and COVID-19: The Story so Far
Fodil S, Annane D
ImmunoTargets and Therapy 2021, 10:273-284
Published Date: 26 July 2021
Cannabis and Autoimmunity: Possible Mechanisms of Action
Giorgi V, Marotto D, Batticciotto A, Atzeni F, Bongiovanni S, Sarzi-Puttini P
ImmunoTargets and Therapy 2021, 10:261-271
Published Date: 21 July 2021
The Cancer-Immunity Cycle in Multiple Myeloma
Casey M, Nakamura K
ImmunoTargets and Therapy 2021, 10:247-260
Published Date: 16 July 2021
Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era
Kasarello K, Mirowska-Guzel D
ImmunoTargets and Therapy 2021, 10:237-246
Published Date: 7 July 2021
Targeting CD22 for the Treatment of B-Cell Malignancies
Shah NN, Sokol L
ImmunoTargets and Therapy 2021, 10:225-236
Published Date: 6 July 2021
Next-Generation Allergen-Specific Immunotherapy for Japanese Cedar Pollinosis Using Molecular Approaches
Takaiwa F
ImmunoTargets and Therapy 2021, 10:213-224
Published Date: 2 July 2021
CD38-Directed Therapies for Management of Multiple Myeloma
Hashmi H, Husnain M, Khan A, Usmani SZ
ImmunoTargets and Therapy 2021, 10:201-211
Published Date: 29 June 2021
VISTA: A Promising Target for Cancer Immunotherapy?
Tagliamento M, Agostinetto E, Borea R, Brandão M, Poggio F, Addeo A, Lambertini M
ImmunoTargets and Therapy 2021, 10:185-200
Published Date: 22 June 2021
Memory Generation and Re-Activation in Food Allergy
Koenig JFE, Bruton K, Phelps A, Grydziuszko E, Jiménez-Saiz R, Jordana M
ImmunoTargets and Therapy 2021, 10:171-184
Published Date: 9 June 2021
NHS-IL12, a Tumor-Targeting Immunocytokine
Greiner JW, Morillon II YM, Schlom J
ImmunoTargets and Therapy 2021, 10:155-169
Published Date: 27 May 2021
Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis
Atzeni F, Carriero A, Boccassini L, D'Angelo S
ImmunoTargets and Therapy 2021, 10:141-153
Published Date: 3 May 2021
Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
Xu N, Tse B, Yang L, Tang TCY, Haber M, Micklethwaite K, Dolnikov A
ImmunoTargets and Therapy 2021, 10:123-140
Published Date: 28 April 2021
TNFR2: Role in Cancer Immunology and Immunotherapy
Yang Y, Islam MS, Hu Y, Chen X
ImmunoTargets and Therapy 2021, 10:103-122
Published Date: 21 April 2021
Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?
Held F, Klein AK, Berthele A
ImmunoTargets and Therapy 2021, 10:87-101
Published Date: 19 March 2021
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
Hasan A, Al-Ozairi E, Al-Baqsumi Z, Ahmad R, Al-Mulla F
ImmunoTargets and Therapy 2021, 10:63-85
Published Date: 9 March 2021
Soluble IL-7Rα/sCD127 in Health, Disease, and Its Potential Role as a Therapeutic Agent
Barros PO, Berthoud TK, Aloufi N, Angel JB
ImmunoTargets and Therapy 2021, 10:47-62
Published Date: 8 March 2021
Anti-IgE for the Treatment of Chronic Urticaria
Wedi B, Traidl S
ImmunoTargets and Therapy 2021, 10:27-45
Published Date: 17 February 2021
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Passiglia F, Reale ML, Cetoretta V, Novello S
ImmunoTargets and Therapy 2021, 10:9-26
Published Date: 5 February 2021
Current Insights into Immunotherapy Approaches for Food Allergy
Macdougall JD, Burks AW, Kim EH
ImmunoTargets and Therapy 2021, 10:1-8
Published Date: 27 January 2021
IgA and FcαRI: Versatile Players in Homeostasis, Infection, and Autoimmunity
van Gool MMJ, van Egmond M
ImmunoTargets and Therapy 2020, 9:351-372
Published Date: 5 January 2021
Acetylcholine Regulates Pulmonary Pathology During Viral Infection and Recovery
Horkowitz AP, Schwartz AV, Alvarez CA, Herrera EB, Thoman ML, Chatfield DA, Osborn KG, Feuer R, George UZ, Phillips JA
ImmunoTargets and Therapy 2020, 9:333-350
Published Date: 17 December 2020
Complement Inhibition for the Treatment of Myasthenia Gravis
Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P
ImmunoTargets and Therapy 2020, 9:317-331
Published Date: 15 December 2020
Development of Anti-Yersinia pestis Human Antibodies with Features Required for Diagnostic and Therapeutic Applications
Lillo AM, Velappan N, Kelliher JM, Watts AJ, Merriman SP, Vuyisich G, Lilley LM, Coombs KE, Mastren T, Teshima M, Stein BW, Wagner GL, Iyer S, Bradbury ARM, Harris JF, Dichosa AE, Kozimor SA
ImmunoTargets and Therapy 2020, 9:299-316
Published Date: 27 November 2020
All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective
Jefremow A, Neurath MF
ImmunoTargets and Therapy 2020, 9:289-297
Published Date: 26 November 2020
Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
Sepe P, Mennitto A, Corti F, Procopio G
ImmunoTargets and Therapy 2020, 9:273-288
Published Date: 13 November 2020
Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR
ImmunoTargets and Therapy 2020, 9:255-272
Published Date: 10 November 2020
Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases
Tanaka Y, Hoshino-Negishi K, Kuboi Y, Tago F, Yasuda N, Imai T
ImmunoTargets and Therapy 2020, 9:241-253
Published Date: 4 November 2020